文献速递胸部肿瘤

CCTG BR34:度伐利尤单抗联合替西木单抗联合或不联合铂类化疗治疗转移性非小细胞肺癌的随机2期试验

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-11-17

这项在加拿大和澳大利亚44个中心开展的开放标签随机2期试验,将301例无EGFR或ALK敏感突变的初治转移性NSCLC患者按1:1随机分配接受度伐利尤单抗联合替西木单抗联合或不联合铂类双药化疗。主要终点总生存期在化疗联合免疫治疗组为16.6个月,免疫治疗组为14.1个月(HR=0.88,90%CI 0.67-1.16,p=0.46)。作者结论认为在度伐利尤单抗联合替西木单抗基础上加化疗未改善生存。

要点

  • 化疗联合免疫治疗组中位OS 16.6个月 vs 免疫治疗组14.1个月(HR=0.88,90%CI 0.67-1.16,p=0.46)。
  • 化疗联合免疫治疗组中位PFS 7.7个月 vs 免疫治疗组3.2个月(HR=0.67,95%CI 0.52-0.88)。
  • 化疗联合免疫治疗组ORR 42.4% vs 免疫治疗组29.3%(校正OR=1.69,95%CI 1.04-2.76)。

核心结论

  • 在IV期NSCLC一线治疗中,度伐利尤单抗联合替西木单抗基础上加用化疗与单用度伐利尤单抗联合替西木单抗相比未改善生存。
  • 作者认为需要进一步研究以识别哪些患者从单纯初始免疫治疗 versus 化疗联合免疫治疗一线治疗中获益。

研究设计与样本

  • 开放标签、随机2期临床试验,在加拿大和澳大利亚44个中心开展。
  • 纳入初治、转移性NSCLC且无EGFR或ALK敏感突变的患者,按1:1随机分配接受度伐利尤单抗联合替西木单抗联合或不联合铂类双药化疗。
  • 共301例患者被随机分配。
  • 主要终点为总生存期(OS);次要终点为无进展生存期、总缓解率和安全性。

主要发现

  • 化疗联合免疫治疗组中位OS为16.6个月(95%CI 12.6-19.1),免疫治疗组为14.1个月(95%CI 10.6-18.3)(HR=0.88,90%CI 0.67-1.16,p=0.46)。
  • 化疗联合免疫治疗组中位PFS为7.7个月(95%CI 5.5-8.5),免疫治疗组为3.2个月(95%CI 2.7-5.1)(HR=0.67,95%CI 0.52-0.88)。
  • 化疗联合免疫治疗组ORR为42.4%,免疫治疗组为29.3%(校正OR=1.69,95%CI 1.04-2.76)。
  • 化疗联合免疫治疗组3级或以上不良事件发生率为82%,免疫治疗组为70%。
  • 对PD-L1表达和基于血液的肿瘤突变负荷的探索性分析未发现OS的治疗效果差异。

临床怎么用

  • 作者结论认为在度伐利尤单抗联合替西木单抗基础上加化疗未改善生存,并认为需要进一步研究识别从单纯初始免疫治疗 versus 化疗联合免疫治疗中获益的患者。

局限性

  • 作者认为需要进一步研究以识别哪些患者从单纯初始免疫治疗 versus 化疗联合免疫治疗一线治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: First-line therapy for patients with metastatic NSCLC includes checkpoint inhibitor monotherapy, dual checkpoint inhibition, or combination with chemotherapy. We compared outcomes with combination chemoimmunotherapy versus dual checkpoint inhibition as first-line treatment for patients with metastatic NSCLC. METHODS: This open-label, randomized clinical trial was conducted at 44 sites in Canada and Australia. Patients with treatment-naive, metastatic NSCLC without sensitizing EGFR or ALK alterations were randomized (1:1) to receive treatment with durvalumab plus tremelimumab with or without platinum-doublet chemotherapy. The primary end point was overall survival (OS). Secondary end points were progression-free survival, overall response rate, and safety. RESULTS: A total of 301 patients were randomized. Median OS was 16.6 months (95% confidence interval [CI]: 12.6-19.1) with chemotherapy plus immunotherapy and 14.1 months (95% CI: 10.6-18.3) with immunotherapy (hazard ratio = 0.88, 90% CI: 0.67-1.16, p = 0.46). Median progression-free survival with chemotherapy plus immunotherapy was 7.7 months (95% CI: 5.5-8.5) and 3.2 months (95% CI: 2.7-5.1) with immunotherapy (hazard ratio = 0.67, 95% CI: 0.52-0.88). The overall response rate with chemoimmunotherapy was 42.4% and 29.3% with immunotherapy (adjusted OR = 1.69, 95% CI: 1.04-2.76). The percentage of patients with grade 3 or higher adverse events was 82% in the chemotherapy plus immunotherapy group and 70% in the immunotherapy group. Exploratory analyses of programmed death-ligand 1 expression and blood-based tumor mutation burden revealed no differential treatment effect on OS. CONCLUSIONS: The addition of chemotherapy to durvalumab plus tremelimumab in the first-line treatment of stage IV NSCLC did not improve survival compared with durvalumab plus tremelimumab alone. Further study is warranted to identify patients that benefit from initial immunotherapy alone versus combination chemotherapy plus immunotherapy as first-line treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Leighl NB, Laurie SA, Goss GD, et al. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. J Thorac Oncol. 2021. PMID: 34800700. doi:10.1016/j.jtho.2021.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。